<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02386371</url>
  </required_header>
  <id_info>
    <org_study_id>ICM-URC2014/07</org_study_id>
    <nct_id>NCT02386371</nct_id>
  </id_info>
  <brief_title>Intraoperative Radiotherapy After Local Recurrence in Breast Cancer</brief_title>
  <acronym>RE-IORT01</acronym>
  <official_title>Feasibility Clinical Trial of Intraoperative Radiotherapy (IORT) and Second Breast-conserving-surgery After Local Recurrence of Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a prospective, multicenter, single arm Phase II design to evaluate&#xD;
      the feasibility of repeated breast-conserving surgery combined with re- irradiation using&#xD;
      IORT after local recurrence of breast carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, the rate of ipsilateral breast tumor recurrence (IBTR) after breast- conserving&#xD;
      surgery and radiotherapy remains at 10% at 10 years to 15% at 20 years, respectively. IBTR is&#xD;
      an independent predictor of poor survival with a 3 to 4.6 increased risk of cancer-related&#xD;
      death.&#xD;
&#xD;
      In a heterogeneous population, local control remains a major therapeutic challenge for these&#xD;
      relapses, especially those considered of better prognosis, namely occurring late and of low&#xD;
      histological grade. Therapeutic de-escalation is possible for these relapses to avoid a&#xD;
      mutilating and often traumatic mastectomy.&#xD;
&#xD;
      However, this second conservative surgery has a high rate of second local relapse (19 to 50%&#xD;
      at 5 years) due to the absence of a re-irradiation, rendered impossible by the problem of&#xD;
      tolerance of previously irradiated tissues.&#xD;
&#xD;
      Retrospective or prospective studies on partial breast irradiation (PBI) in adjuvant setting&#xD;
      report promising results, both in terms of tolerance (saving healthy tissue) and local&#xD;
      control (74% to 100% at 5 years). Used techniques include brachytherapy, external beam&#xD;
      radiotherapy and intraoperative radiotherapy (IORT).&#xD;
&#xD;
      IORT is now the subject of renewed interest in breast cancer. It has the advantages of&#xD;
      high-precision ballistics on the operated area and of preservation of healthy tissue. To&#xD;
      date, no prospective data, however, have been published in the indication of ipsilateral&#xD;
      breast recurrence.&#xD;
&#xD;
      A prospective, multicenter, single arm Phase II design will evaluate the feasibility of&#xD;
      repeated breast-conserving surgery combined with re- irradiation using IORT after local&#xD;
      recurrence of breast carcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Actual">June 12, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerance of intra operative radiation as assessed by acute and late toxicities</measure>
    <time_frame>up to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cosmetic outcome evaluated by photography</measure>
    <time_frame>up to 5 years</time_frame>
    <description>To</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>surgery and Intra Operative Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgery :&#xD;
Tumorectomy will be performed according to the current standards, obtaining &quot;clear&quot; margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.&#xD;
Intra Operative Radiotherapy (IORT):&#xD;
After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tumorectomy</intervention_name>
    <description>Tumorectomy will be performed according to the current standards, obtaining &quot;clear&quot; margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams.</description>
    <arm_group_label>surgery and Intra Operative Radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intra Operative Radiotherapy</intervention_name>
    <description>After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure</description>
    <arm_group_label>surgery and Intra Operative Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven non-lobular invasive breast recurrence&#xD;
&#xD;
          -  Time from whole breast radiation following the initial lumpectomy &gt;5 years&#xD;
&#xD;
          -  Unifocal tumor&#xD;
&#xD;
          -  Recurrent tumor size ≤ 2 cm&#xD;
&#xD;
          -  Adequate breast size for a second breast-conserving surgery with acceptable cosmetic&#xD;
             result&#xD;
&#xD;
          -  Bilateral breast mammogram within 90 days prior to study entry&#xD;
&#xD;
          -  Breast MRI within 90 days prior to study entry&#xD;
&#xD;
          -  Histological grade I-II&#xD;
&#xD;
          -  Estrogen-receptor-positive tumor (ER+)&#xD;
&#xD;
          -  Cerb2-negative tumor&#xD;
&#xD;
          -  N0&#xD;
&#xD;
          -  M0&#xD;
&#xD;
          -  Prior radiotherapy delivered within a standard fractionation schedule&#xD;
&#xD;
          -  Performance status (ECOG) 0-1&#xD;
&#xD;
          -  Women ≥ 50 years -Absence of any psychological, familial, sociological, or&#xD;
             geographical conditions with a potential to hamper compliance with the study and&#xD;
             follow- up schedule&#xD;
&#xD;
          -  Affiliated to the French Health Insurance regimen&#xD;
&#xD;
          -  Written and signed informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multifocal and/or multicenter recurrence&#xD;
&#xD;
          -  Lobular carcinoma&#xD;
&#xD;
          -  Estrogen-receptor-negative tumor (ER-)&#xD;
&#xD;
          -  Cerb2 (her2) overexpressed - breast cancer&#xD;
&#xD;
          -  Extensive intraductal component (EIC) on biopsy&#xD;
&#xD;
          -  Lymph vessel invasion on biopsy&#xD;
&#xD;
          -  N1-3 status: Regional cytological or histologically proven node recurrence&#xD;
&#xD;
          -  M1 status: Metastatic disease&#xD;
&#xD;
          -  cT4 (Skin or muscle involvement) or Paget's disease of the nipple&#xD;
&#xD;
          -  Prior radiotherapy delivered within an accelerated or hypo-fraction schedule&#xD;
&#xD;
          -  Prior malignancy other than non-melanoma skin cancer unless the patient has been&#xD;
             disease free for at least 5 years&#xD;
&#xD;
          -  Patients with a small breast volume, technically unsatisfactory for a second&#xD;
             conservative surgery or intraoperative breast irradiation.&#xD;
&#xD;
          -  Preoperative chemotherapy or hormone therapy for local relapse&#xD;
&#xD;
          -  Connective tissue disease or scleroderma, contraindicating radiotherapy&#xD;
&#xD;
          -  Known BRCA1/2 gene mutation (genetic testing is not required)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DOMERGUE Jacques</last_name>
    <role>Study Director</role>
    <affiliation>Institut régional du Cancer - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre George Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002 Oct 17;347(16):1233-41.</citation>
    <PMID>12393820</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002 Oct 17;347(16):1227-32.</citation>
    <PMID>12393819</PMID>
  </reference>
  <reference>
    <citation>Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, Booser DJ, Valero V, Bondy M, Esteva FJ. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83. doi: 10.1093/jnci/djn233. Epub 2008 Aug 11.</citation>
    <PMID>18695137</PMID>
  </reference>
  <reference>
    <citation>Panet-Raymond V, Truong PT, Alexander C, Lesperance M, McDonald RE, Watson PH. Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence. Cancer. 2011 May 15;117(10):2035-43. doi: 10.1002/cncr.25767. Epub 2010 Nov 29.</citation>
    <PMID>21523714</PMID>
  </reference>
  <reference>
    <citation>Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011 Nov 12;378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Review.</citation>
    <PMID>22019144</PMID>
  </reference>
  <reference>
    <citation>Kurtz JM, Spitalier JM, Amalric R, Brandone H, Ayme Y, Jacquemier J, Hans D, Bressac C. The prognostic significance of late local recurrence after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):87-93.</citation>
    <PMID>2298639</PMID>
  </reference>
  <reference>
    <citation>Hannoun-Levi JM, Resch A, Gal J, Kauer-Dorner D, Strnad V, Niehoff P, Loessl K, Kovács G, Van Limbergen E, Polgár C; GEC-ESTRO Breast Cancer Working Group. Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol. 2013 Aug;108(2):226-31. doi: 10.1016/j.radonc.2013.03.026. Epub 2013 May 3.</citation>
    <PMID>23647758</PMID>
  </reference>
  <reference>
    <citation>Moran MS, Haffty BG. Local-regional breast cancer recurrence: prognostic groups based on patterns of failure. Breast J. 2002 Mar-Apr;8(2):81-7.</citation>
    <PMID>11896752</PMID>
  </reference>
  <reference>
    <citation>Fourquet A, Campana F, Zafrani B, Mosseri V, Vielh P, Durand JC, Vilcoq JR. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys. 1989 Oct;17(4):719-25.</citation>
    <PMID>2777661</PMID>
  </reference>
  <reference>
    <citation>Fisher B, Anderson S, Fisher ER, Redmond C, Wickerham DL, Wolmark N, Mamounas EP, Deutsch M, Margolese R. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet. 1991 Aug 10;338(8763):327-31.</citation>
    <PMID>1677695</PMID>
  </reference>
  <reference>
    <citation>Veronesi U, Marubini E, Del Vecchio M, Manzari A, Andreola S, Greco M, Luini A, Merson M, Saccozzi R, Rilke F, et al. Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst. 1995 Jan 4;87(1):19-27.</citation>
    <PMID>7666458</PMID>
  </reference>
  <reference>
    <citation>Tanis E, van de Velde CJ, Bartelink H, van de Vijver MJ, Putter H, van der Hage JA. Locoregional recurrence after breast-conserving therapy remains an independent prognostic factor even after an event free interval of 10 years in early stage breast cancer. Eur J Cancer. 2012 Aug;48(12):1751-6. doi: 10.1016/j.ejca.2012.02.051. Epub 2012 Mar 23.</citation>
    <PMID>22446021</PMID>
  </reference>
  <reference>
    <citation>Schmoor C, Sauerbrei W, Bastert G, Schumacher M. Role of isolated locoregional recurrence of breast cancer: results of four prospective studies. J Clin Oncol. 2000 Apr;18(8):1696-708.</citation>
    <PMID>10764430</PMID>
  </reference>
  <reference>
    <citation>Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol. 2009 May 20;27(15):2466-73. doi: 10.1200/JCO.2008.19.8424. Epub 2009 Apr 6.</citation>
    <PMID>19349544</PMID>
  </reference>
  <reference>
    <citation>van der Sangen MJ, van de Poll-Franse LV, Roumen RM, Rutten HJ, Coebergh JW, Vreugdenhil G, Voogd AC. The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast carcinoma. Eur J Surg Oncol. 2006 Feb;32(1):34-8. Epub 2005 Nov 21.</citation>
    <PMID>16305821</PMID>
  </reference>
  <reference>
    <citation>Galper S, Blood E, Gelman R, Abner A, Recht A, Kohli A, Wong JS, Smith D, Bellon J, Connolly J, Schnitt S, Winer E, Silver B, Harris JR. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):348-57.</citation>
    <PMID>15667952</PMID>
  </reference>
  <reference>
    <citation>Lê MG, Arriagada R, Spielmann M, Guinebretière JM, Rochard F. Prognostic factors for death after an isolated local recurrence in patients with early-stage breast carcinoma. Cancer. 2002 Jun 1;94(11):2813-20.</citation>
    <PMID>12115367</PMID>
  </reference>
  <reference>
    <citation>Courdi A, Doyen J, Gal J, Chamorey E. Local recurrence after breast cancer affects specific survival differently according to patient age. Oncology. 2010;79(5-6):349-54. doi: 10.1159/000323483. Epub 2011 Mar 23.</citation>
    <PMID>21430403</PMID>
  </reference>
  <reference>
    <citation>Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S, Saieva C, Paiar F, Scotti V, De Luca Cardillo C, Bastiani P, Orzalesi L, Casella D, Sanchez L, Nori J, Fambrini M, Bianchi S. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015 Mar;51(4):451-463. doi: 10.1016/j.ejca.2014.12.013. Epub 2015 Jan 17.</citation>
    <PMID>25605582</PMID>
  </reference>
  <reference>
    <citation>Sabatier R, Finetti P, Cervera N, Tallet A, Benchalal M, Houvenaeghel G, Jacquemier J, Birnbaum D, Bertucci F. Gene expression profiling and its utility in prediction of local relapse after breast-conserving therapy in early breast cancer. Cancer Genomics Proteomics. 2011 Jul-Aug;8(4):199-209.</citation>
    <PMID>21737613</PMID>
  </reference>
  <reference>
    <citation>Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D, Bressac C, Spitalier JM. Is breast conservation after local recurrence feasible? Eur J Cancer. 1991;27(3):240-4.</citation>
    <PMID>1827303</PMID>
  </reference>
  <reference>
    <citation>Salvadori B, Marubini E, Miceli R, Conti AR, Cusumano F, Andreola S, Zucali R, Veronesi U. Reoperation for locally recurrent breast cancer in patients previously treated with conservative surgery. Br J Surg. 1999 Jan;86(1):84-7.</citation>
    <PMID>10027366</PMID>
  </reference>
  <reference>
    <citation>Alpert TE, Kuerer HM, Arthur DW, Lannin DR, Haffty BG. Ipsilateral breast tumor recurrence after breast conservation therapy: outcomes of salvage mastectomy vs. salvage breast-conserving surgery and prognostic factors for salvage breast preservation. Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):845-51.</citation>
    <PMID>16199315</PMID>
  </reference>
  <reference>
    <citation>Gentilini O, Botteri E, Veronesi P, Sangalli C, Del Castillo A, Ballardini B, Galimberti V, Rietjens M, Colleoni M, Luini A, Veronesi U. Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol. 2012 Nov;19(12):3771-6. doi: 10.1245/s10434-012-2404-5. Epub 2012 May 23.</citation>
    <PMID>22618719</PMID>
  </reference>
  <reference>
    <citation>Deutsch M. Repeat high-dose external beam irradiation for in-breast tumor recurrence after previous lumpectomy and whole breast irradiation. Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):687-91.</citation>
    <PMID>12062613</PMID>
  </reference>
  <reference>
    <citation>Hannoun-Levi JM, Ihrai T, Courdi A. Local treatment options for ipsilateral breast tumour recurrence. Cancer Treat Rev. 2013 Nov;39(7):737-41. doi: 10.1016/j.ctrv.2013.02.003. Epub 2013 Mar 5. Review.</citation>
    <PMID>23465859</PMID>
  </reference>
  <reference>
    <citation>Chadha M, Feldman S, Boolbol S, Wang L, Harrison LB. The feasibility of a second lumpectomy and breast brachytherapy for localized cancer in a breast previously treated with lumpectomy and radiation therapy for breast cancer. Brachytherapy. 2008 Jan-Mar;7(1):22-8. doi: 10.1016/j.brachy.2007.10.006.</citation>
    <PMID>18299110</PMID>
  </reference>
  <reference>
    <citation>Trombetta M, Julian TB, Werts ED, Colonias A, Betler J, Kotinsley K, Kim Y, Parda D. Comparison of conservative management techniques in the re-treatment of ipsilateral breast tumor recurrence. Brachytherapy. 2011 Jan-Feb;10(1):74-80. doi: 10.1016/j.brachy.2010.01.005. Epub 2010 Aug 4.</citation>
    <PMID>20685174</PMID>
  </reference>
  <reference>
    <citation>Wapnir IL, Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Mamounas EP, Wolmark N. Progress on BIG 1-02/IBCSG 27-02/NSABP B-37, a prospective randomized trial evaluating chemotherapy after local therapy for isolated locoregional recurrences of breast cancer. Ann Surg Oncol. 2008 Nov;15(11):3227-31. doi: 10.1245/s10434-008-0129-2. Epub 2008 Sep 11.</citation>
    <PMID>18784962</PMID>
  </reference>
  <reference>
    <citation>Aebi S, Gelber S, Anderson SJ, Láng I, Robidoux A, Martín M, Nortier JW, Paterson AH, Rimawi MF, Cañada JM, Thürlimann B, Murray E, Mamounas EP, Geyer CE Jr, Price KN, Coates AS, Gelber RD, Rastogi P, Wolmark N, Wapnir IL; CALOR investigators. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol. 2014 Feb;15(2):156-63. doi: 10.1016/S1470-2045(13)70589-8. Epub 2014 Jan 16.</citation>
    <PMID>24439313</PMID>
  </reference>
  <reference>
    <citation>Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF, Thürlimann B, Cavalli F, Obrecht JP, et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research. J Clin Oncol. 1994 Oct;12(10):2071-7.</citation>
    <PMID>7931476</PMID>
  </reference>
  <reference>
    <citation>Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner KW, Borner MM; Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol. 2003 Aug;14(8):1215-21.</citation>
    <PMID>12881382</PMID>
  </reference>
  <reference>
    <citation>Doyle T, Schultz DJ, Peters C, Harris E, Solin LJ. Long-term results of local recurrence after breast conservation treatment for invasive breast cancer. Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):74-80.</citation>
    <PMID>11516854</PMID>
  </reference>
  <reference>
    <citation>Abner AL, Recht A, Eberlein T, Come S, Shulman L, Hayes D, Connolly JL, Schnitt SJ, Silver B, Harris JR. Prognosis following salvage mastectomy for recurrence in the breast after conservative surgery and radiation therapy for early-stage breast cancer. J Clin Oncol. 1993 Jan;11(1):44-8.</citation>
    <PMID>8418240</PMID>
  </reference>
  <reference>
    <citation>Voogd AC, van Tienhoven G, Peterse HL, Crommelin MA, Rutgers EJ, van de Velde CJ, van Geel BN, Slot A, Rodrigus PT, Jobsen JJ, von Meyenfeldt MF, Coebergh JW. Local recurrence after breast conservation therapy for early stage breast carcinoma: detection, treatment, and outcome in 266 patients. Dutch Study Group on Local Recurrence after Breast Conservation (BORST). Cancer. 1999 Jan 15;85(2):437-46.</citation>
    <PMID>10023713</PMID>
  </reference>
  <reference>
    <citation>Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, Klimberg S, Chavez-MacGregor M, Freedman G, Houssami N, Johnson PL, Morrow M; Society of Surgical Oncology; American Society for Radiation Oncology. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. J Clin Oncol. 2014 May 10;32(14):1507-15. doi: 10.1200/JCO.2013.53.3935. Epub 2014 Feb 10.</citation>
    <PMID>24516019</PMID>
  </reference>
  <reference>
    <citation>Dalberg K, Mattsson A, Sandelin K, Rutqvist LE. Outcome of treatment for ipsilateral breast tumor recurrence in early-stage breast cancer. Breast Cancer Res Treat. 1998 May;49(1):69-78.</citation>
    <PMID>9694613</PMID>
  </reference>
  <reference>
    <citation>Ishitobi M, Komoike Y, Nakahara S, Motomura K, Koyama H, Inaji H. Repeat lumpectomy for ipsilateral breast tumor recurrence after breast-conserving treatment. Oncology. 2011;81(5-6):381-6. doi: 10.1159/000335265. Epub 2012 Jan 20.</citation>
    <PMID>22269927</PMID>
  </reference>
  <reference>
    <citation>Chen SL, Martinez SR. The survival impact of the choice of surgical procedure after ipsilateral breast cancer recurrence. Am J Surg. 2008 Oct;196(4):495-9. doi: 10.1016/j.amjsurg.2008.06.018.</citation>
    <PMID>18809050</PMID>
  </reference>
  <reference>
    <citation>Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985 Sep 1;56(5):979-90.</citation>
    <PMID>2990668</PMID>
  </reference>
  <reference>
    <citation>Smith TE, Lee D, Turner BC, Carter D, Haffty BG. True recurrence vs. new primary ipsilateral breast tumor relapse: an analysis of clinical and pathologic differences and their implications in natural history, prognoses, and therapeutic management. Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1281-9.</citation>
    <PMID>11121624</PMID>
  </reference>
  <reference>
    <citation>Fredriksson I, Liljegren G, Arnesson LG, Emdin SO, Palm-Sjövall M, Fornander T, Holmqvist M, Holmberg L, Frisell J. Local recurrence in the breast after conservative surgery--a study of prognosis and prognostic factors in 391 women. Eur J Cancer. 2002 Sep;38(14):1860-70.</citation>
    <PMID>12204668</PMID>
  </reference>
  <reference>
    <citation>Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010 Jul 10;376(9735):91-102. doi: 10.1016/S0140-6736(10)60837-9. Erratum in: Lancet. 2010 Jul 10;376(9735):90.</citation>
    <PMID>20570343</PMID>
  </reference>
  <reference>
    <citation>Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, Julian TB, Marks LB, Todor DA, Vicini FA, Whelan TJ, White J, Wo JY, Harris JR. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg. 2009 Aug;209(2):269-77. doi: 10.1016/j.jamcollsurg.2009.02.066. Epub 2009 Apr 24.</citation>
    <PMID>19632605</PMID>
  </reference>
  <reference>
    <citation>Polgár C, Van Limbergen E, Pötter R, Kovács G, Polo A, Lyczek J, Hildebrandt G, Niehoff P, Guinot JL, Guedea F, Johansson B, Ott OJ, Major T, Strnad V; GEC-ESTRO breast cancer working group. Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009). Radiother Oncol. 2010 Mar;94(3):264-73. doi: 10.1016/j.radonc.2010.01.014. Epub 2010 Feb 22.</citation>
    <PMID>20181402</PMID>
  </reference>
  <reference>
    <citation>Hannoun-Levi JM, Houvenaeghel G, Ellis S, Teissier E, Alzieu C, Lallement M, Cowen D. Partial breast irradiation as second conservative treatment for local breast cancer recurrence. Int J Radiat Oncol Biol Phys. 2004 Dec 1;60(5):1385-92.</citation>
    <PMID>15590169</PMID>
  </reference>
  <reference>
    <citation>Resch A, Fellner C, Mock U, Handl-Zeller L, Biber E, Seitz W, Pötter R. Locally recurrent breast cancer: pulse dose rate brachytherapy for repeat irradiation following lumpectomy-- a second chance to preserve the breast. Radiology. 2002 Dec;225(3):713-8.</citation>
    <PMID>12461250</PMID>
  </reference>
  <reference>
    <citation>Kraus-Tiefenbacher U, Bauer L, Scheda A, Schoeber C, Schaefer J, Steil V, Wenz F. Intraoperative radiotherapy (IORT) is an option for patients with localized breast recurrences after previous external-beam radiotherapy. BMC Cancer. 2007 Sep 14;7:178.</citation>
    <PMID>17854511</PMID>
  </reference>
  <reference>
    <citation>Kauer-Dorner D, Pötter R, Resch A, Handl-Zeller L, Kirchheiner K, Meyer-Schell K, Dörr W. Partial breast irradiation for locally recurrent breast cancer within a second breast conserving treatment: alternative to mastectomy? Results from a prospective trial. Radiother Oncol. 2012 Jan;102(1):96-101. doi: 10.1016/j.radonc.2011.07.020. Epub 2011 Sep 8.</citation>
    <PMID>21907439</PMID>
  </reference>
  <reference>
    <citation>Guix B, Lejárcegui JA, Tello JI, Zanón G, Henríquez I, Finestres F, Martínez A, Fernandez-Ibiza J, Quinzaños L, Palombo P, Encinas X, Guix I. Exeresis and brachytherapy as salvage treatment for local recurrence after conservative treatment for breast cancer: results of a ten-year pilot study. Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):804-10. doi: 10.1016/j.ijrobp.2009.08.009. Epub 2010 Jan 26.</citation>
    <PMID>20106605</PMID>
  </reference>
  <reference>
    <citation>Nairz O, Deutschmann H, Kopp M, Wurstbauer K, Kametriser G, Fastner G, Merz F, Reitsamer R, Menzel C, Sedlmayer F. A dosimetric comparison of IORT techniques in limited-stage breast cancer. Strahlenther Onkol. 2006 Jun;182(6):342-8.</citation>
    <PMID>16703290</PMID>
  </reference>
  <reference>
    <citation>Herskind C, Griebel J, Kraus-Tiefenbacher U, Wenz F. Sphere of equivalence--a novel target volume concept for intraoperative radiotherapy using low-energy X rays. Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1575-81. doi: 10.1016/j.ijrobp.2008.08.009.</citation>
    <PMID>19028280</PMID>
  </reference>
  <reference>
    <citation>Liu Q, Schneider F, Ma L, Wenz F, Herskind C. Relative Biologic Effectiveness (RBE) of 50 kV X-rays measured in a phantom for intraoperative tumor-bed irradiation. Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):1127-33. doi: 10.1016/j.ijrobp.2012.08.005. Epub 2012 Sep 14.</citation>
    <PMID>22981707</PMID>
  </reference>
  <reference>
    <citation>Reitsamer R, Fastner G, Kopp M, Menzel C, Sedlmayer F. Intraoperative radiotherapy for early breast cancer. Lancet. 2010 Oct 2;376(9747):1141; author reply 1143-4. doi: 10.1016/S0140-6736(10)61529-2.</citation>
    <PMID>20888980</PMID>
  </reference>
  <reference>
    <citation>Smith BD, Buchholz TA, Kuerer HM. Intraoperative radiotherapy for early breast cancer. Lancet. 2010 Oct 2;376(9747):1141; author reply 1143-4. doi: 10.1016/S0140-6736(10)61530-9.</citation>
    <PMID>20888981</PMID>
  </reference>
  <reference>
    <citation>Reitsamer R, Sedlmayer F, Kopp M, Kametriser G, Menzel C, Deutschmann H, Nairz O, Hitzl W, Peintinger F. The Salzburg concept of intraoperative radiotherapy for breast cancer: results and considerations. Int J Cancer. 2006 Jun 1;118(11):2882-7.</citation>
    <PMID>16381011</PMID>
  </reference>
  <reference>
    <citation>Dubois JB, Hay M, Gely S, Saint-Aubert B, Rouanet P, Pujol H. IORT in breast carcinomas. Front Radiat Ther Oncol. 1997;31:131-7.</citation>
    <PMID>9263806</PMID>
  </reference>
  <reference>
    <citation>Fastner G, Sedlmayer F, Merz F, Deutschmann H, Reitsamer R, Menzel C, Stierle C, Farmini A, Fischer T, Ciabattoni A, Mirri A, Hager E, Reinartz G, Lemanski C, Orecchia R, Valentini V. IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: long term results of an ISIORT pooled analysis. Radiother Oncol. 2013 Aug;108(2):279-86. doi: 10.1016/j.radonc.2013.05.031. Epub 2013 Jul 2.</citation>
    <PMID>23830467</PMID>
  </reference>
  <reference>
    <citation>Lemanski C, Azria D, Thezenas S, Gutowski M, Saint-Aubert B, Rouanet P, Fenoglietto P, Ailleres N, Dubois JB. Intraoperative radiotherapy given as a boost for early breast cancer: long-term clinical and cosmetic results. Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1410-5. Epub 2006 Jan 25.</citation>
    <PMID>16442241</PMID>
  </reference>
  <reference>
    <citation>Lemanski C, Azria D, Gourgon-Bourgade S, Gutowski M, Rouanet P, Saint-Aubert B, Ailleres N, Fenoglietto P, Dubois JB. Intraoperative radiotherapy in early-stage breast cancer: results of the montpellier phase II trial. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):698-703. doi: 10.1016/j.ijrobp.2009.02.039. Epub 2009 May 23.</citation>
    <PMID>19467579</PMID>
  </reference>
  <reference>
    <citation>Welzel G, Boch A, Sperk E, Hofmann F, Kraus-Tiefenbacher U, Gerhardt A, Suetterlin M, Wenz F. Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomized phase III trial TARGIT-A. Radiat Oncol. 2013 Jan 7;8:9. doi: 10.1186/1748-717X-8-9.</citation>
    <PMID>23294485</PMID>
  </reference>
  <reference>
    <citation>Sperk E, Welzel G, Keller A, Kraus-Tiefenbacher U, Gerhardt A, Sütterlin M, Wenz F. Late radiation toxicity after intraoperative radiotherapy (IORT) for breast cancer: results from the randomized phase III trial TARGIT A. Breast Cancer Res Treat. 2012 Aug;135(1):253-60. doi: 10.1007/s10549-012-2168-4. Epub 2012 Jul 29.</citation>
    <PMID>22842984</PMID>
  </reference>
  <reference>
    <citation>Grobmyer SR, Lightsey JL, Bryant CM, Shaw C, Yeung A, Bhandare N, Hitchingham B, Copeland EM 3rd. Low-kilovoltage, single-dose intraoperative radiation therapy for breast cancer: results and impact on a multidisciplinary breast cancer program. J Am Coll Surg. 2013 Apr;216(4):617-23; discussion 623-4. doi: 10.1016/j.jamcollsurg.2012.12.038. Epub 2013 Feb 14.</citation>
    <PMID>23415885</PMID>
  </reference>
  <reference>
    <citation>Keshtgar MR, Williams NR, Bulsara M, Saunders C, Flyger H, Cardoso JS, Corica T, Bentzon N, Michalopoulos NV, Joseph DJ. Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial. Breast Cancer Res Treat. 2013 Aug;140(3):519-25. doi: 10.1007/s10549-013-2641-8. Epub 2013 Jul 23.</citation>
    <PMID>23877341</PMID>
  </reference>
  <reference>
    <citation>Dubois JB, Gu SD, Hay MH, Gely S, Delard R, Joyeux H, Solassol C, Pujol H. Intra-operative radiation therapy (IORT) with 100 kV X photons. Experience on 170 patients. Pathol Biol (Paris). 1992 Nov;39(9):884-5.</citation>
    <PMID>1538921</PMID>
  </reference>
  <reference>
    <citation>Lemanski C, Azria D, Gourgou-Bourgade S, Ailleres N, Pastant A, Rouanet P, Fenoglietto P, Dubois JB, Gutowski M. Electrons for intraoperative radiotherapy in selected breast-cancer patients: late results of the Montpellier phase II trial. Radiat Oncol. 2013 Aug 1;8:191. doi: 10.1186/1748-717X-8-191.</citation>
    <PMID>23902825</PMID>
  </reference>
  <reference>
    <citation>Neumaier C, Elena S, Grit W, Yasser AM, Uta KT, Anke K, Axel G, Marc S, Frederik W. TARGIT-E(lderly)--prospective phase II study of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer. BMC Cancer. 2012 May 8;12:171. doi: 10.1186/1471-2407-12-171.</citation>
    <PMID>22569123</PMID>
  </reference>
  <reference>
    <citation>Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, Moscardo CL, Lemanski C, Coelho M, Rosenstein B, Fenoglietto P, Crompton NE, Ozsahin M. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol. 2010 Mar;11(3):258-65. doi: 10.1016/S1470-2045(10)70013-9. Epub 2010 Feb 6.</citation>
    <PMID>20138810</PMID>
  </reference>
  <reference>
    <citation>Ozsahin M, Crompton NE, Gourgou S, Kramar A, Li L, Shi Y, Sozzi WJ, Zouhair A, Mirimanoff RO, Azria D. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res. 2005 Oct 15;11(20):7426-33.</citation>
    <PMID>16243816</PMID>
  </reference>
  <reference>
    <citation>Rothkamm K, Beinke C, Romm H, Badie C, Balagurunathan Y, Barnard S, Bernard N, Boulay-Greene H, Brengues M, De Amicis A, De Sanctis S, Greither R, Herodin F, Jones A, Kabacik S, Knie T, Kulka U, Lista F, Martigne P, Missel A, Moquet J, Oestreicher U, Peinnequin A, Poyot T, Roessler U, Scherthan H, Terbrueggen B, Thierens H, Valente M, Vral A, Zenhausern F, Meineke V, Braselmann H, Abend M. Comparison of established and emerging biodosimetry assays. Radiat Res. 2013 Aug;180(2):111-9. doi: 10.1667/RR3231.1. Epub 2013 Jul 17.</citation>
    <PMID>23862692</PMID>
  </reference>
  <reference>
    <citation>Templin T, Paul S, Amundson SA, Young EF, Barker CA, Wolden SL, Smilenov LB. Radiation-induced micro-RNA expression changes in peripheral blood cells of radiotherapy patients. Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):549-57. doi: 10.1016/j.ijrobp.2010.12.061. Epub 2011 Mar 21.</citation>
    <PMID>21420249</PMID>
  </reference>
  <reference>
    <citation>Park SH, Kim MJ, Park BW, Moon HJ, Kwak JY, Kim EK. Impact of preoperative ultrasonography and fine-needle aspiration of axillary lymph nodes on surgical management of primary breast cancer. Ann Surg Oncol. 2011 Mar;18(3):738-44. doi: 10.1245/s10434-010-1347-y. Epub 2010 Oct 2.</citation>
    <PMID>20890729</PMID>
  </reference>
  <reference>
    <citation>MacNeill M, Arnott I, Thomas J. Fine needle aspiration cytology is a valuable adjunct to axillary ultrasound in the preoperative staging of breast cancer. J Clin Pathol. 2011 Jan;64(1):42-6. doi: 10.1136/jcp.2010.083063. Epub 2010 Nov 19.</citation>
    <PMID>21097541</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2015</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

